|
SI1485127T1
(sl)
|
2002-02-25 |
2011-09-30 |
Elan Pharm Inc |
Dajanje aktivne snovi za zdravljenje vnetja
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
US9415102B2
(en)
*
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
|
ES2614274T3
(es)
*
|
2002-09-06 |
2017-05-30 |
Alexion Pharmaceuticals, Inc. |
Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5
|
|
AU2004210679A1
(en)
*
|
2003-02-10 |
2004-08-26 |
Elan Pharmaceuticals, Inc. |
Immunoglobulin formulation and method of preparation thereof
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
JP2007531738A
(ja)
*
|
2004-04-02 |
2007-11-08 |
アムジエン・インコーポレーテツド |
ＩＬ−１ｒａの凝集を低下させる方法
|
|
CA2478458A1
(en)
*
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
JP2008520717A
(ja)
*
|
2004-11-19 |
2008-06-19 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
多発性硬化症についての処置
|
|
LT2620450T
(lt)
*
|
2005-03-08 |
2019-02-11 |
Pfizer Products Inc. |
Anti-ctla-4 antikūnų kompozicijos
|
|
EP1888637A2
(en)
*
|
2005-05-19 |
2008-02-20 |
Amgen Inc. |
Compositions and methods for increasing the stability of antibodies
|
|
AR057807A1
(es)
*
|
2005-09-12 |
2007-12-19 |
Novimmune Sa |
Formulaciones de anticuerpo anti-cd3
|
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
|
RS55963B1
(sr)
|
2005-12-29 |
2017-09-29 |
Janssen Biotech Inc |
Humana anti-il-23 antitela, kompozicije, metode i upotrebe
|
|
ES2965283T3
(es)
|
2006-03-15 |
2024-05-28 |
Alexion Pharma Inc |
Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
|
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
AU2007300221A1
(en)
*
|
2006-09-25 |
2008-04-03 |
Medimmune, Llc. |
Stabilized antibody formulations and uses thereof
|
|
EP2081553B1
(en)
*
|
2006-10-06 |
2020-08-12 |
Amgen Inc. |
Stable antibody formulations
|
|
JP5623743B2
(ja)
|
2006-10-20 |
2014-11-12 |
アムジエン・インコーポレーテツド |
安定なポリペプチド製剤
|
|
WO2008086395A2
(en)
*
|
2007-01-09 |
2008-07-17 |
Wyeth |
Anti-il-13 antibody formulations and uses thereof
|
|
CA2677831A1
(fr)
*
|
2007-02-12 |
2008-08-21 |
Lassaad Boujbel |
Le sucralose solution sterile sans conservateurs
|
|
NZ595526A
(en)
*
|
2007-06-14 |
2013-03-28 |
Biogen Idec Inc |
Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
|
|
US20090208492A1
(en)
*
|
2007-06-14 |
2009-08-20 |
Elan Pharmaceuticals, Inc. |
Lyophilized Immunoglobulin Formulations and Methods of Preparation
|
|
WO2009003010A2
(en)
*
|
2007-06-25 |
2008-12-31 |
Becton, Dickinson And Company |
Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
|
|
ES2543735T3
(es)
*
|
2007-10-22 |
2015-08-21 |
Becton Dickinson And Company |
Artículos médicos revestidos con organopolisiloxano que contienen una disolución de proteína y un tensioactivo no iónico
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
TWI532498B
(zh)
|
2008-03-17 |
2016-05-11 |
巴克斯特保健公司 |
供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
|
|
WO2009124294A2
(en)
*
|
2008-04-05 |
2009-10-08 |
Lpath, Inc. |
Pharmaceutical compositions for binding sphingosine-1-phosphate
|
|
PT2271382E
(pt)
|
2008-04-15 |
2013-05-07 |
Grifols Therapeutics Inc |
Ultrafiltração em dois andares/diafiltração
|
|
EP2331078B1
(en)
|
2008-08-27 |
2012-09-19 |
Merck Sharp & Dohme Corp. |
Lyophilized formulations of engineered anti-il-23p19 antibodies
|
|
TWI516501B
(zh)
*
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Ｐｃｓｋ９拮抗劑類
|
|
MX2011005672A
(es)
*
|
2008-11-28 |
2011-06-20 |
Abbott Lab |
Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
|
|
JP5372170B2
(ja)
*
|
2008-12-29 |
2013-12-18 |
サミャン バイオファーマシューティカルズ コーポレイション |
凍結乾燥剤形の薬剤学的組成物及びその製造方法
|
|
FR2940617B1
(fr)
*
|
2008-12-30 |
2012-04-20 |
Fractionnement Et Des Biotechonologies Lab Franc |
Composition d'immunoglobulines g
|
|
WO2010121141A1
(en)
*
|
2009-04-17 |
2010-10-21 |
Biogen Idec Ma Inc. |
Compositions and methods to treat acute myelogenous leukemia
|
|
NZ595694A
(en)
*
|
2009-05-04 |
2013-09-27 |
Abbvie Biotechnology Ltd |
Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
|
|
CN102655853B
(zh)
*
|
2009-09-17 |
2015-07-29 |
巴克斯特卫生保健有限公司 |
透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法
|
|
SI2485761T1
(sl)
*
|
2009-10-09 |
2019-05-31 |
Armagen, Inc. |
Postopki in sestavki za povečanje aktivnosti iduronat-2-sulfataze v CŽS
|
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
|
EP3409289B1
(en)
|
2010-02-26 |
2020-09-30 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
|
EA201291065A1
(ru)
|
2010-04-16 |
2013-03-29 |
Байоджен Айдек Ма Инк. |
Антитела против vla-4
|
|
RU2012153786A
(ru)
|
2010-05-28 |
2014-07-10 |
Ново Нордиск А/С |
Стабильные многодозовые композиции, содержащие антитело и консервант
|
|
PT3170508T
(pt)
|
2010-06-04 |
2020-01-16 |
Wyeth Llc |
Formulações de vacinas
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EA032336B1
(ru)
*
|
2010-09-17 |
2019-05-31 |
Баксалта Инкорпорейтид |
Стабильная водная иммуноглобулиновая композиция и способ стабилизации иммуноглобулиновой композиции
|
|
ES3005233T3
(en)
|
2010-10-01 |
2025-03-14 |
Modernatx Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
WO2012061074A1
(en)
|
2010-10-25 |
2012-05-10 |
Elan Pharmaceuticals, Inc. |
METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
|
|
CN103458926B
(zh)
|
2010-11-11 |
2016-10-26 |
艾伯维生物技术有限公司 |
改进的高浓度抗TNF α 抗体液体制剂
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
MX341076B
(es)
|
2011-03-31 |
2016-08-04 |
Merck Sharp & Dohme |
Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
|
|
CN103619349A
(zh)
*
|
2011-05-26 |
2014-03-05 |
葛兰素史密丝克莱恩生物有限公司 |
灭活登革热病毒疫苗
|
|
MX421100B
(es)
|
2011-07-01 |
2025-02-10 |
Biogen Ma Inc |
Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2763701B1
(en)
|
2011-10-03 |
2018-12-19 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
JP2015501844A
(ja)
|
2011-12-16 |
2015-01-19 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
|
|
NZ627859A
(en)
*
|
2012-01-23 |
2015-09-25 |
Regeneron Pharma |
Stabilized formulations containing anti-ang2 antibodies
|
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
|
EP4527855A3
(en)
*
|
2012-03-26 |
2025-06-11 |
Sanofi |
Stable igg4 based binding agent formulations
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
AR091902A1
(es)
|
2012-07-25 |
2015-03-11 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de un conjugado de insulina de accion prolongada
|
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
EP2727602A1
(en)
*
|
2012-10-31 |
2014-05-07 |
Takeda GmbH |
Method for preparation of a high concentration liquid formulation of an antibody
|
|
ES2921623T3
(es)
|
2012-11-26 |
2022-08-30 |
Modernatx Inc |
ARN modificado terminalmente
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
WO2015035342A2
(en)
|
2013-09-08 |
2015-03-12 |
Oligasis Llc |
Factor viii zwitterionic polymer conjugates
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
HRP20241036T1
(hr)
|
2013-11-21 |
2024-11-08 |
Genmab A/S |
Liofilizirana formulacija konjugata protutijelo-lijek
|
|
WO2015095568A1
(en)
*
|
2013-12-18 |
2015-06-25 |
Kelvin Lee |
Reduction of lipase activity in product formulations
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
KR20210013299A
(ko)
|
2014-10-17 |
2021-02-03 |
코디악 사이언시스 인코포레이티드 |
부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
|
|
AR104847A1
(es)
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
WO2017015198A1
(en)
*
|
2015-07-17 |
2017-01-26 |
Coherus Biosciences, Inc. |
Stable aqeous formulations of natalizumab
|
|
US10484453B2
(en)
*
|
2015-07-29 |
2019-11-19 |
Xerox Corporation |
System and method for printing documents using print hardware and automatic context inference
|
|
KR20250057128A
(ko)
|
2015-12-30 |
2025-04-28 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
|
MX2018008300A
(es)
|
2016-01-13 |
2018-09-21 |
Genmab As |
Formulacion para anticuerpo y conjugado de farmaco del mismo.
|
|
ES2797298T3
(es)
|
2016-02-10 |
2020-12-01 |
Becton Dickinson France |
Procedimiento para evaluar la estabilidad de una formulación a base de proteína
|
|
EP3541413A2
(en)
|
2016-11-21 |
2019-09-25 |
Polpharma Biologics S.A. |
Aqueous pharmaceutical formulations
|
|
RU2019138507A
(ru)
|
2017-05-02 |
2021-06-02 |
Мерк Шарп И Доум Корп. |
Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
ES2938608T3
(es)
*
|
2017-09-20 |
2023-04-13 |
Tillotts Pharma Ag |
Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
|
|
BR112020011414B8
(pt)
|
2017-12-06 |
2023-01-31 |
Merck Sharp & Dohme |
Composições imunogênicas multivalentes compreendendo conjugados de proteína carreadora e polissacarídeo de s. pneumoniae
|
|
MX2020005981A
(es)
*
|
2017-12-08 |
2020-08-24 |
Argenx Bvba |
Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
|
|
US12582809B2
(en)
|
2018-01-26 |
2026-03-24 |
Bt Bidco, Inc. |
Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor
|
|
US12071476B2
(en)
|
2018-03-02 |
2024-08-27 |
Kodiak Sciences Inc. |
IL-6 antibodies and fusion constructs and conjugates thereof
|
|
ES3064335T3
(en)
|
2018-03-05 |
2026-04-24 |
Janssen Biotech Inc |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
WO2019173767A1
(en)
|
2018-03-08 |
2019-09-12 |
Coherus Biosciences Inc. |
Stable aqueous formulations of aflibercept
|
|
US11426446B2
(en)
|
2018-03-08 |
2022-08-30 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
TWI841554B
(zh)
|
2018-03-21 |
2024-05-11 |
丹麥商珍美寶股份有限公司 |
以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
|
|
EP3773694A4
(en)
*
|
2018-04-10 |
2021-12-29 |
Dr. Reddy's Laboratories Ltd. |
Antibody formulation
|
|
BR112020020741A2
(pt)
*
|
2018-04-10 |
2021-01-19 |
Dr. Reddy's Laboratories Limited |
Formulação farmacêutica estável de um anticorpo, e, formulação de anticorpo alfa4beta7 estável.
|
|
CN112292146A
(zh)
|
2018-04-10 |
2021-01-29 |
雷迪博士实验室有限公司 |
治疗性抗体的稳定的制剂
|
|
CA3099547A1
(en)
|
2018-05-07 |
2019-11-14 |
Reshma Abdulla RANGWALA |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
|
JP7457661B2
(ja)
|
2018-06-04 |
2024-03-28 |
バイオジェン・エムエイ・インコーポレイテッド |
低減したエフェクター機能を有する抗ｖｌａ－４抗体
|
|
EP3802590A2
(en)
|
2018-06-08 |
2021-04-14 |
Argenx BVBA |
Compositions and methods for treating immune thrombocytopenia
|
|
US12227565B2
(en)
|
2018-06-20 |
2025-02-18 |
Biora Therapeutics, Inc. |
Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
|
|
US20230312700A1
(en)
|
2018-06-20 |
2023-10-05 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
|
EP3810085A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
|
EP3810268A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
|
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
US12171764B2
(en)
|
2018-06-20 |
2024-12-24 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
|
|
US11738068B2
(en)
|
2018-06-25 |
2023-08-29 |
Jcr Pharmaceuticals Co., Ltd. |
Protein-containing aqueous liquid formulation
|
|
CN113056482A
(zh)
|
2018-10-18 |
2021-06-29 |
默沙东公司 |
抗rsv抗体的制剂及其使用方法
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
CN120842406A
(zh)
|
2018-10-31 |
2025-10-28 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
KR20210089215A
(ko)
|
2018-11-07 |
2021-07-15 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체 및 항-pd-1 항체의 공동-제제
|
|
MX2021005905A
(es)
|
2018-11-20 |
2021-06-23 |
Janssen Biotech Inc |
Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23.
|
|
EP3897705A2
(en)
|
2018-12-19 |
2021-10-27 |
Merck Sharp & Dohme Corp. |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
|
US12409221B2
(en)
|
2018-12-24 |
2025-09-09 |
Grand Theravac Life Sciences (Nanjing) Co., Ltd. |
Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof
|
|
US11780911B2
(en)
|
2019-05-23 |
2023-10-10 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
|
|
EP3980063A1
(en)
*
|
2019-06-07 |
2022-04-13 |
Argenx BVBA |
Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration
|
|
MX2021015213A
(es)
*
|
2019-06-11 |
2022-01-18 |
Macrogenics Inc |
Formulaciones farmaceuticas de diacuerpos biespecificos y uso de las mismas.
|
|
CN114630678A
(zh)
*
|
2019-08-01 |
2022-06-14 |
詹森生物科技公司 |
FcRn抗体及其使用方法
|
|
WO2021050687A1
(en)
|
2019-09-10 |
2021-03-18 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
AU2020364071A1
(en)
|
2019-10-10 |
2022-05-26 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
JP7718272B2
(ja)
*
|
2019-12-16 |
2025-08-05 |
ニプロ株式会社 |
凝集防止剤ならびにそれを用いた医薬組成物および医療用デバイス
|
|
KR20220148804A
(ko)
|
2020-01-08 |
2022-11-07 |
아르젠엑스 비브이 |
천포창 장애의 치료 방법
|
|
KR20220140500A
(ko)
*
|
2020-01-13 |
2022-10-18 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
약물 전달 시스템 성분에 대한 치료제 단백질의 흡착을 방지하기 위한 방법 및 조성물
|
|
JP2023512991A
(ja)
*
|
2020-01-29 |
2023-03-30 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｌａｇ３抗体生成からの宿主細胞リパーゼの分離方法
|
|
MX2022014430A
(es)
|
2020-05-21 |
2023-02-22 |
Janssen Biotech Inc |
Método para tratar la enfermedad inflamatoria del intestino con una terapia de combinación de anticuerpos para il-23 y tnf alfa.
|
|
EP4243859A4
(en)
*
|
2020-11-12 |
2024-10-16 |
Dr. Reddy's Laboratories Ltd. |
STABLE AQUEOUS FORMULATION WITH HIGH CONCENTRATION OF ANTI-INTEGRIN ANTIBODY
|
|
EP4493592A1
(en)
|
2022-03-14 |
2025-01-22 |
LamKap Bio gamma AG |
Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
|
|
CA3258004A1
(en)
|
2022-06-15 |
2023-12-21 |
argenx BV |
FCRN/HSA BONDING MOLECULES AND METHODS OF USE
|
|
TW202504919A
(zh)
|
2023-05-30 |
2025-02-01 |
美商派拉岡醫療公司 |
α4β7整合素抗體組合物及使用方法
|
|
CN121889424A
(zh)
|
2023-08-14 |
2026-04-17 |
派拉冈医疗公司 |
α4β7整联蛋白结合蛋白及使用方法
|